Application And Significance Of Polyethylene Glycol Recombinant Human Granulocyte Stimulating Factor In The Treatment Of DLBCL

Objective:To explore the prophylactic application and significance of pegylated recombinant human granulocyte colony-stimulating factor for chemotherapy-induced neutropenia in patients with diffuse large B cell lymphoma.Methods:Clinical records of DLBCL patients from November 2016 to March 2019 were retrospectively reviewed and analyzed.Between the primary prevention group,the secondary prevention group and the control group,the incidence of chemotherapy-induced neutropenia,febrile neutropenia,timely chemotherapy rate,complete response rate,the cost,long-term survival and the safety were recorded and compared.Results:1.The incidence of grade Ⅲ neutropenia in the primary prevention group was 3.03%,6.06%,3.03%,6.06%in each chemotherapy cycle.The incidence of grade Ⅳ neutropenia was 3.03%,3.03%,9.09%,6.06%.The incidence of grade Ⅲ neutropenia in the secondary prevention group was 19.04%,9.52%,14.29%,14.29%in each chemotherapy cycle.The incidence of grade Ⅳneutropenia was 19.04%,4.74%,4.74%,9.52%.The incidence of grade Ⅲ neutropenia in the control group was 23.08%,15.38%,15.38%,19.23%in each chemotherapy cycle.The incidence of gradeⅣ neutropenia was 19.23%,15.38%,11.54%,11.54%.Compared with the secondary prevention group,the incidence of Ⅲ-Ⅳ neutropenia were significantly lower in the primary prevention group in the first cycle of chemotherapy(P<0.05).Compared with the control group,the incidence of ⅢIV neutropenia were significantly lower in the primary prevention group in the first cycle of chemotherapy(P<0.05).There was no significant difference in other cycles of chemotherapy.2.Compared with the control group,the incidence of FN in the primary prevention group was lower than that in the control group after the first cycle of chemotherapy(P<0.05).About the utilization rate of antibiotics,the primary prevention group was lower than the secondary prevention group after the first chemotherapy cycle,with a statistical difference(P<0.05);the primary prevention group after the 1 and 4 chemotherapy cycles were significantly lower than that in the control group,with a statistical difference(P<0.05).3.The timely chemotherapy rate in the primary prevention group was significantly higher than that in the secondary prevention group in the 1,2 cycles of chemotherapy(P<0.05).The timely chemotherapy rate in the primary prevention group were higher than that in the control group in all chemotherapy cycles(P<0.05).The timely chemotherapy rate in the secondary prevention group was significantly higher than that in the control group in the 3,4 cycles of chemotherapy(P<0.05).4.There was no significant difference in the three groups about the CR rate(P>0.05).5.The hospitalization days and the cost of the primary prevention group(6.25d,(?)(11711.92)were significantly lower than those of the control group(9.95d,(?)15725.68)(P<0.05),6.There was no significant difference in the three groups about the 2-year PFS and 2-year OS(P>0.05).7.The adverse reactions associated with PEG-rhG-CSF accounted for 5.56%.Conclusion:Application of PEG-rhG-CSF in the treatment of DLBCL chemotherapy can effectively reduce the incidence of neutropenia and the incidence of FN after chemotherapy,ensure timely chemotherapy,reduce the hospitalization days and is cost-effective.